Free Trial

2seventy bio Q2 2023 Earnings Report

2seventy bio logo
$4.96 0.00 (0.00%)
As of 12:08 PM Eastern

2seventy bio EPS Results

Actual EPS
-$0.83
Consensus EPS
-$1.04
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$36.05 million
Expected Revenue
$31.81 million
Beat/Miss
Beat by +$4.24 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

2seventy bio Earnings Headlines

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

View 2seventy bio Profile

More Earnings Resources from MarketBeat